Literature DB >> 7566765

A survey of allopurinol dosage prescribing.

A D McClintock1, A J Egan, D J Woods, P I Pillans.   

Abstract

AIM: To evaluate the appropriateness of allopurinol dosage according to renal function in patients at Dunedin and Wakari hospitals.
METHOD: A prospective survey of all patients receiving allopurinol therapy at Dunedin and Wakari hospitals during a four week period in January/February 1994 was performed. Data were collected from medication charts, patient notes and laboratory records. Dosage prescribed was compared with established guidelines.
RESULTS: Of 46 patients on allopurinol treatment 18 were prescribed at least 100 mg more than the recommended daily dose. Twenty-nine out of the 46 surveyed patients (median age 77 years) had mild to moderate renal impairment.
CONCLUSIONS: A significant proportion of patients were receiving excessive doses. Although information regarding the allopurinol hypersensitivity syndrome and individualised allopurinol dosage is available, it is evident that many practitioners remain unaware of the recommendations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7566765

Source DB:  PubMed          Journal:  N Z Med J        ISSN: 0028-8446


  4 in total

1.  Quality of care for gout in the US needs improvement.

Authors:  Jasvinder A Singh; James S Hodges; John P Toscano; Steven M Asch
Journal:  Arthritis Rheum       Date:  2007-06-15

Review 2.  Management of gout in general practice--a systematic review.

Authors:  Andrew Jeyaruban; Sarah Larkins; Muriel Soden
Journal:  Clin Rheumatol       Date:  2014-09-17       Impact factor: 2.980

3.  Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations.

Authors:  Edward Roddy; Weiya Zhang; Michael Doherty
Journal:  Ann Rheum Dis       Date:  2007-05-15       Impact factor: 19.103

Review 4.  Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

Authors:  Sheena N Ramasamy; Cameron S Korb-Wells; Diluk R W Kannangara; Myles W H Smith; Nan Wang; Darren M Roberts; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.228

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.